MAPT and dementia: In dementia research and clinical practice, although the biomarkers exist on a continuum, dichotomizing normal/abnormal tau using specific cut-points is useful and widely used.44 We tried to predict the tau positivity obtained from the ground-truth tau-PET data using four different meta-ROI cut-off thresholds (SUVR = 1.11, 1.21, 1.33 and 1.46) with the AI-imputed tau-PET.